Montelukast TEVA 4 mg 28 chewable tablets

Montelukast-TEVA chewable tablets 4 mg, 28 pcs

Composition:
active substance: montelukast sodium;
1 chewable tablet contains montelukast 4 mg as montelukast sodium; excipients: mannitol (E 421), sodium lauryl sulfate, hydroxypropyl cellulose, iron oxide red (E172), cherry flavor PHS-143671, aspartame (E 951), sodium starch (type A), magnesium stearate.

Pharmacotherapeutic group:
Means for systemic use in obstructive respiratory diseases. Leukotriene receptor antagonists. ATX code R03D C03.

Indications:
Montelukast-Teva 4 mg chewable tablets are recommended for children 2 to 5 years of age:

• as an additional treatment of bronchial asthma in patients with persistent mild and moderate asthma, which is insufficiently controlled by inhaled GCS, as well as in case of insufficient clinical control of asthma using short-acting β-agonists, used if necessary;
• as an alternative method of treatment in relation to low doses of inhaled corticosteroids in patients with persistent mild asthma who have not recently had serious asthma attacks requiring corticosteroid intake, as well as for those patients who have been found to be intolerant to inhaled corticosteroids;
• prophylactically before physical activity to prevent an asthmatic attack.

Contraindications:
Hypersensitivity to montelukast or to any component of the drug.

Method of administration and dosage:
The drug should be used in children under adult supervision.

Children aged 2 to 5 years. The recommended dose is 1 4 mg chewable tablet per day, in the evening. Take Montelukast-Teva 1 hour before or 2 hours after a meal. For patients in this group, individual dose selection is not needed.

Children between the ages of 6 and 14. The recommended dose is 1 chewable tablet, 5 mg per day, in the evening. Take Montelukast-Teva 1 hour before or 2 hours after a meal. For patients in this group, individual dose selection is not needed. Patients over 15 years of age are advised to use Montelukast-Teva, film-coated tablets, 10 mg.

General recommendations
The therapeutic effect of the drug Montelukast-Teva on asthma control indicators occurs within 1 day. Patients are advised to continue using Montelukast-Teva, even if the manifestations of their asthma are under control, as well as during its exacerbation.

Special patient groups
Dose adjustment is not required for patients with renal impairment or mild to moderate hepatic impairment. There are no data on patients with severe liver dysfunction. The dosage of the drug for boys and girls is the same.

Alternative therapy with low-dose inhaled corticosteroids in patients with persistent mild asthma
Montelukast-Teva is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative to low-dose inhaled corticosteroids for children 2-5 years old with persistent mild asthma is recommended only for those patients who have not recently had serious asthma attacks requiring corticosteroids and who have been found to be intolerant of inhaled corticosteroids.

Mild persistent asthma is asthma with symptoms more than 1 time per week, but less often than 1 time per day, night attacks more often than 2 attacks per month, but less often than 1 time per week with normal lung function between attacks.

If satisfactory control of bronchial asthma is achieved after treatment (usually within one month), it is necessary to consider the need for additional or other anti-inflammatory therapy, based on a stepwise system of treatment of bronchial asthma. You should also periodically assess the condition of patients for the control of bronchial asthma. If children have difficulty taking a chewable tablet, the drug should be taken in granular form.

Preventive prevention of exercise-induced asthma
in children 2-5 years of age In children 2-5 years of age, exercise-induced bronchospasm may be the dominant indicator of persistent asthma, requiring treatment with inhaled corticosteroids. Patients should be assessed after 2-4 weeks of Montelukast-Teva treatment. If a satisfactory clinical response to therapy is not achieved, additional or other therapy should be considered.

Montelukast-Teva and other medications for asthma
When treatment with montelukast is used as an adjunct therapy to inhaled corticosteroids, Montelukast-Teva should not be abruptly substituted for inhaled corticosteroids.